John E. Souness

Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNFα generation from human monocytes by interacting with a ‘low‐affinity’ phosphodiesterase 4 conformer

John E. Souness, Miriam Griffin, Christopher Maslen et al. · British Journal of Pharmacology · 1996 · 115 citations · Full text

Immunology, Tnf Alpha, Inflammation +17

Anti‐inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor

David Raeburn, Stephen L. Underwood, S.A. Lewis et al. · British Journal of Pharmacology · 1994 · 109 citations · Full text

Characterization of guinea-pig eosinophil phosphodiesterase activity

John E. Souness, Caroline M. Carter, Baljeet K. Diocee et al. · Biochemical Pharmacology · 1991 · 105 citations

Physiology, Eosinophilic Disorder, Cellular Biochemistry +1

Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22,948, MY‐5445, vinpocetine and 1‐methyl‐3‐isobutyl‐8‐(methylamino)xanthine

John E. Souness, R Brazdil, Baljeet K. Diocee et al. · British Journal of Pharmacology · 1989 · 80 citations · Full text

The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy

Iain M. McLay, Frank Halley, John E. Souness et al. · Bioorganic & Medicinal Chemistry · 2001 · 78 citations

Rheumatoid Disorder, Rheumatology, Anti-inflammatory +8